Background and objective: The cornerstone of dermatomyositis (DM) pathogenesis involves vascular disturbance that leads to hypoxia, capillary necrosis and muscle perifascicular atrophy. Hence, the hypothesis is that the angiotensinconverting enzyme (ACE) insertion/deletion (I/D) gene polymorphism could be associated with susceptibility to DM. Method: A single centre, case control study that genotyped ACE gene in 88 DM and 99 healthy individuals. The ACE gene polymorphism was determined by melting curve analysis of real-time polymerase chain reaction products using SYBR Green. Results: The DM and the control subjects had a comparable mean age, gender frequency and ethnicity. The frequency of the D allele was higher in DM than in the control individuals (63.6% vs 55.6%, respectively). The DM had more ACE D/D and less ACE I/D genotype when compared to the control individuals, whereas the ACE I/I genotype distribution was similar in both case and control groups. Moreover, after sex-age-adjusted analysis, the ACE D/D genotype was strongly associated with DM disease (odds ratio (OR) 2.44, 95% confidence interval (CI): 1.17-4.37), in contrast to ACE I/D genotype (OR 0.51, 95% CI: 0.28-0.93). Conclusions: Homozygous ACE D/D was associated significantly with the DM risk. Further investigations are required to clarify and to confirm the association of these genes with DM susceptibility.
Introduction
Dermatomyositis (DM) is a systemic idiopathic inflammatory myopathy characterized by a subacute onset and proximal, symmetrical muscle weakness and is also associated with cutaneous manifestations, including heliotrope and Gottron's papules. 1 The cornerstone of DM pathogenesis involves vascular disturbances that lead to hypoxia, capillary necrosis and muscle perifascicular atrophy. 1, 2 The insertion/deletion (I/D) polymorphism of the angiotensin-converting enzyme (ACE) gene in an intron of the ACE gene, is in strong linkage disequilibrium with genetic factors that influence serum ACE concentrations. 3 ACE is expressed in a wide range of tissues including the lung, vascular endothelium, kidney, and heart. 4 In addition, ACE plays an important role in blood vessel pathogenesis because it catalyses the conversion of angiotensin I to angiotensin II, a vasoactive peptide and growth factor that contributes to vascular reactivity, tissue remodeling and fibrosis, 5,6 vascular smooth muscle cell contraction, smooth muscle proliferation, monocyte adhesion, and platelet adhesion and aggregation. Therefore, as DM pathogenesis involves vascular changes and vasculitis, it is plausible that ACE polymorphism could also be involved in this disease.
Furthermore, angiotensin II is also a potent proinflammatory modulator that augments and possibly perpetuates immune responses, 6 such as those that are characteristic of systemic inflammatory diseases other than DM, including juvenile rheumatoid arthritis, 7 rheumatoid arthritis, 8 and systemic lupus erythematosus (SLE) [9] [10] [11] [12] Indeed, there are some studies that have found that ACE polymorphism is associated with an increase in susceptibility to SLE and lupus nephritis. [9] [10] [11] [12] [13] [14] Nevertheless, to our knowledge, no studies to date have analyzed the ACE gene polymorphism in DM. Moreover, this polymorphism could be an attractive candidate among the factors that play a role in the development of vascular pathological and systemic inflammatory states; therefore, contributing to DM susceptibility and/or DM pathogenesis.
Materials and methods

Study design
The present case control study was performed at a single centre and included 88 DM patients and 99 healthy control individuals from June 2012-January 2013. All of the DM patients met at least four of the five Bohan and Peter criteria, 15 and they were treated at the myopathies unit of our tertiary service. Healthy individuals aged under 18 years and/or with other associated systemic autoimmune diseases were excluded. The study was approved by the local ethics committee, and all of the participants signed an informed consent form.
Patient data
All of the participants underwent a clinical evaluation that included a standardized interview, and all of their medical charts were extensively reviewed and obtained retrospectively. The following data were collected: (a) the patient's age at disease onset and disease duration, gender, and ethnicity; (b) comorbidity prior to DM symptoms/diagnosis, such as systemic arterial hypertension, type 2 diabetes mellitus, hypothyroidism, myocardium infarction, and ischemic stroke; (c) lifestyle features (tobacco and alcohol use); and (d) family history of cardiovascular disease (CVD) (myocardial infarction and sudden death in first degree relatives before age 55 years for men and before age 65 years for women). In addition, laboratory features were collected at the interview day: the serum levels of creatine kinase (normal range: 24-173 U/l) and aldolase (normal range: 1.0-7.5 U/l) were obtained using automated kinetic methods; antinuclear antibodies were detected by indirect immunofluorescence using HEp-2 cells as the substrate; a myositis-specific autoantibody anti-Mi-2 assessment was performed using a commercially available line blot test kit (Myositis Profile Euroline Blot test kit, Euroimmun, Lübeck, Germany) and was used according to the manufacturer's protocol.
ACE genotype determination
To genotype the I/D polymorphism of the ACE gene, genomic DNA was isolated from peripheral blood, and quantitative real-time polymerase chain reaction (qRT-PCR) was performed for the ACE gene I/D allele using the SYBR Green I. The amplification mixtures, at a final volume of 10 µl, included 25 ng genomic DNA, 5 µl 2×Maxima SYBR Green qPCR Master Mix (Fermentas Life Sciences, Burlington Ontario, Canada), and forward (F) and reverse (R) primers at a final concentration of 100 nM. The following primer sequences (5´-3´), synthesized by Eurofins MWG Operon (Huntsville, Alabama, USA), were used: ACE1F, CATCCTTTCTCCCATTTCTCT'; ACE2InsF, TGGGATTACAGGCGTGATACA; and ACE3R, 'GCTGGAATAAAATTGGCGAA. The reactions were performed using an ABI 7500 Real-Time PCR System (Applied Biosystems, Foster City, California, USA). The cycle conditions included incubation at 50˚C for 2 min, initial denaturation at of 95˚C for 10 min, and 40 cycles at 95˚C for 15 s and 60˚C for 1 min. After the amplification was complete, a melting curve analysis was performed by cooling the reaction to 60°C and then heating slowly to 95°C, following the instructions of the manufacturer (Applied Biosystems). The melting curve analyses were performed to assay the ACE I/D polymorphism. In addition, the amplified PCR product was separated on 2% agarose gel electrophoresis and visualized using UV light and ethidium bromide staining. PCR products of 57 base pairs (bp) and 75 bp, corresponding to the two melting peaks at 72.9°C and 74°C, represented the I and D alleles, respectively. A set of PCR products at 57 bp and 363 bp for the two melting peaks at 72.9°C and 86.2°C indicated the I allele, and a PCR product at 75 bp for a melting peak at 74°C indicated the D allele ( Figure 1 ).
Statistical analysis
The continuous variables were expressed as means±standard deviation (SD), medians with interquartile range (IQR), or percentages for the categorical variables. All of the data, including the distributions of ACE genotypes (I/I, I/D, D/D) and alleles (I, D) between the two groups (DM patients vs health controls), were compared using the χ 2 test or Fischer's exact test. All of the variables that differed significantly in the univariate analysis were selected for adjustment. The sex-age-adjusted odds ratio (OR) and 95% confidence interval (CI) were calculated using an unconditional logistic model. The value of p<0.05 was considered to be statistically significant. We used the SPSS version 15.0 statistics software (Chicago, USA) to perform the analyses.
Results
The present study included 88 DM patients and 99 healthy control individuals. The DM patients and control subjects had a comparable mean age (39.8±14.4 vs 40.3±12.3 years, respectively; p=0.802), female gender frequency (p=0.313) and white ethnicity frequency (p=0.176) ( Table 1 ). The median DM duration was four years.
Higher frequencies of the following CVD risk factors were observed in the patients compared to the controls: systemic arterial hypertension (34.1% vs 16.2%, patients and controls, respectively; p=0.004), type 2 diabetes mellitus (5.7% vs 0%; p=0.016) and a family history of premature CVD (22.1% vs 9.2%; p=0.020). However, no significant differences were observed in the rates of myocardial infarction (2.3% vs 0%), ischemic stroke (2.3% vs 0%), hypothyroidism (13.6 vs 6.1%), alcohol consumption (2.3% vs 1.0%), or smoking (9.1% vs 10.0%). The serum levels of creatine kinase were comparable between both groups, whereas the aldolase levels were higher in the DM patients. We observed antinuclear antibodies and anti-Mi-2 antibody in 54.5% and 8.0%, respectively, of the DM patients.
The ACE D and I allele distributions were not in Hardy-Weinberg equilibrium (59.4% vs 40.6%, respectively; p<0.001). Furthermore, the frequency of the D allele was higher in the DM patients than in the control individuals (63.6% vs 55.6%, respectively) ( Table 2) .
The DM patients included more ACE D/D and fewer ACE I/D genotypes compared to the control individuals, whereas the distribution of the ACE I/I genotype was similar in both groups ( Table 3 ). The sex-age-adjusted OR indicated that the ACE D/D genotype was strongly associated with DM disease (OR 2.44, 95% CI: 1.17-4.37), in contrast to that of the ACE I/D genotype (OR 0.51, 95% CI 0.28-0.93).
No association was observed between the ACE D/D genotype and cardiovascular risk factors and demographic features of the DM patients (p>0.050).
Discussion
To our knowledge, this is the first study to assess the ACE gene polymorphism in DM patients. We observed that the ACE D/D genotype was significantly associated with a genetic susceptibility to DM.
The ACE gene is located on the long arm of chromosome 17 16 and shows a characteristic I/D polymorphism based on the presence or absence of a 287 bp Alu repeat sequence within intron 16. Accordingly, there are therefore three possible genotypes: I/I, I/D, and D/D. Carriers of the D/D genotype have the highest levels of serum ACE, and those with the I/I genotype have the lowest serum levels. 17 The ACE gene I/D polymorphism is implicated in the pathogenesis of a number of cardiovascular disorders, including myocardial infarction, left ventricular hypertrophy, and systemic arterial hypertension. Furthermore, the ACE gene has been recognized as a potential candidate gene for cardiovascular research. [18] [19] [20] [21] [22] Indeed, the D allele reportedly behaves as a marker of atherosclerotic cardiovascular complications. 23 Therefore, the available evidence supports the notion that the D/D genotype adversely influences specific CVDs.
Moreover, the ACE gene polymorphism had been described in various systemic autoimmune diseases, such as juvenile rheumatoid arthritis, 7 systemic lupus erythematosus, [9] [10] [11] [12] 24, 25 rheumatoid arthritis, 8, 26 spondylarthritis. 27, 28 and systemic sclerosis. [29] [30] [31] Indeed, the presence of the ACE D allele in systemic sclerosis, [29] [30] [31] which involves an increased prevalence of vascular damage, 27 may predispose the individual to an involvement of the macrovascular system. 29, 30 Lupus nephritis is characterized by increasing vascular lesion risk, 13 and some studies have found that the ACE polymorphism was associated with lupus renal involvement. 10, 14 In contrast to these diseases, there is no study thus far that has analyzed the ACE polymorphism in DM, a disease that involves vascular pathogenesis mediated by humoral processes with secondary ischemic changes of muscle fibers. 1, 2, 31, 32 In these conditions, abnormalities have been found in the endothelium of capillaries, arterioles, and veins, which have been suggested to represent primary disease-related alterations. 31, 32 DM is characterized by perifascicular atrophy, perivascular inflammation, microvascular deposits of the C5b-9 membrane attack complex on endothelial cells, and endomysial capillaries that are enlarged and reduced in number, with partial endothelial swelling. [31] [32] [33] Thus, the ACE polymorphism could additionally contribute to the microvascular pathology findings in DM. Furthermore, we have recently observed a high prevalence of metabolic syndrome and CVD parameters, such as stroke and defined-diabetes mellitus, in patients with DM. 34 Nevertheless, these high frequencies of CVD in DM patients may be the result of (a) DM in conjunction with underlying inflammatory processes, which decrease functional capacity. and (b) the treatment of CVD as a comorbid condition in DM patients. However, a previous study shows that high CVD frequencies are not explained by demographic data, traditional risk factors or lifestyle habits (alcohol consumption, tobacco, sedentary). 34 Therefore, we speculate a possible genetic involvement in the physiopathogenesis of DM that also contributes to a high prevalence of metabolic syndrome and CVD parameters. However, we observed the association of the ACE polymorphism with the presence of DM but not with CVDs, most likely because of the limitation of the number of individuals analyzed in the present study.
Another hypothesis for an association between the ACE polymorphism and DM is that the D/D genotype favors angiotensin II production, a potent proinflammatory modulator that augments and perpetuates immune responses, 6 which is also observed in various systemic autoimmune diseases. [7] [8] [9] [10] [11] [12] In summary, we report for the first time the association of the ACE polymorphism with the presence of DM. However, we did not find a relationship between this genotype and CVD parameters in patients with DM, most likely because of the small sample size. Further investigations are required to confirm the possible association of these genes with cardiovascular comorbidities.
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